Cassava Sciences Inc

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cassava Sciences advances Phase III trial with strong financial footing

Cassava Sciences is progressing well with Phase III trial milestones and financial stability, poised to announce critical trial results by year-end.
While facing challenges in data accuracy and increased expenses, the company's proactive approach and strategic planning present significant growth opportunities.
By focusing on innovation and market transformation, Cassava Sciences is positioned to redefine Alzheimer's disease diagnosis and treatment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

CorMedix

CarLotz

NEW YORK, NY / ACCESSWIRE / August 30, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court.

CLASS ACTION UPDATE for LOTZ, CRMD and SAVA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

On behalf of a whistleblower or whistleblowers, the law firm of Labaton Sucharow has asked the FDA to halt Cassava Sciences' clinical trials on the basis of potential data manipulation. Perhaps the whistleblower's most serious charge is that Cassava Sciences turned to its own affiliated lab to overcome poor results reported by an independent lab.

Cassava Sciences And Alzheimer's Disease: Raising Doubts

BlueCity Holdings Limited

Stable Road Acquisition Corp

NEW YORK, NY / ACCESSWIRE / August 29, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment.

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of SRAC, BLCT and SAVA

ATI Physical Therapy

NEW YORK, NY / ACCESSWIRE / August 29, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

SHAREHOLDER ALERT: CRMD ATIP SAVA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

LOS ANGELES--(BUSINESS WIRE)---- $SAVA #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Cassava investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)---- $SAVA #investors--The Law Offices of Frank R. Cruz Continues Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors

The Law Offices of Frank R. Cruz Continues Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors

San Francisco, California--(Newsfile Corp. - August 27, 2021) -  Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.Visit: www.hbsslaw.com/investor-fraud/SAVA Contact An Attorney Now: SAVA@hbsslaw.com 844-916-0895Cassava Sciences, Inc. (SAVA) Investigation: The investigation focuses on whether Cassava misled investors about the integrity of preliminary analysis of a small clinical trial of the company's Alzheimer's drug, simufilam. On July 29, 2021 Cassava...

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Cassava Sciences, Inc. (SAVA) Investors to Contact Firm's Attorneys Now, Firm Investigating Possible Securities Law Violations

Quanterix Corp. took a swing at Cassava Sciences Inc. Friday, but then Cassava hit back, stressing that Quanterix was contracted to perform sample testing of the trial data that have been disputed.

Cassava Sciences punches back, after Qaunterix took a swing by saying it didn't interpret or prepare the disputed trial data

Boston, Massachusetts--(Newsfile Corp. - August 27, 2021) -  Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA), a drug development company. If you sustained losses in excess of $100,000 from your transactions in Cassava securities during the Class Period and are interested in learning more about serving as Lead Plaintiff, please provide your information here: Shareholder Contact |...

SAVA: Berman Tabacco Alerts Investors with Losses of $100,000 from Investments in Cassava Sciences, Inc. of Deadline to Apply to Serve as Lead Plaintiff

BENSALEM, Pa.--(BUSINESS WIRE)---- $SAVA #CLASSACTION--Law Offices of Howard G. Smith continues its investigation on behalf of Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) investors concerning the Company's possible violations of federal securities laws. On August 24, 2021, after the market closed, it was revealed that a Citizen Petition was filed with the United States Food and Drug Administration (“FDA”) requesting that the FDA halt two ongoing trials of Cassava's proprietary drug Simufilam. T

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors

SAN DIEGO, Aug. 27, 2021 /PRNewswire/ --  Robbins Geller Rudman & Dowd LLP today announced that it filed a class action lawsuit charging Cassava Sciences, Inc. (NASDAQ: SAVA) and certain of its executives with violations of the Securities Exchange Act of 1934 and seeking to represent purchasers of Cassava Sciences common stock between February 2, 2021 and August 24, 2021, inclusive (the "Class Period").  The Cassava Sciences class action lawsuit was commenced on August 27, 2021 in the Western District of Texas and is captioned Brazeau v.

SAVA NOTICE: Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Cassava Sciences, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Case

The stock's been a wild ride for investors all year, and it's dropped more than 50% in two days. What's going on, and why am I bullish?

Why the Cassava Sciences Bears Are Wrong

AUSTIN, Texas, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer's disease, today released a statement regarding plasma p-tau analysis from a previously disclosed randomized, controlled Phase 2b clinical study in patients with Alzheimer's disease. For this study, Cassava Sciences contracted with Quanterix Corp., a highly regarded, independent laboratory, to perform sample testing on blinded samples.

Cassava Sciences Releases Statement Regarding Plasma p-tau Analysis from a Previously Disclosed Phase 2b Clinical Study in Alzheimer's Patients

LOS ANGELES, Aug. 27, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ: SAVA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Ongoing Investigation Alert: The Schall Law Firm Announces it is Investigating Claims Against Cassava Sciences, Inc. and Encourages Investors with Losses to Contact the Firm

More red flags are emerging for this troubled Alzheimer's biotech company.

Why Cassava Sciences Is Plunging Again Today

The neurodegenerative diseases-focused biopharma Cassava Sciences, Inc. (NASDAQ: SAVA) has now lost half of its market capitalization.  What Happened: Cassava shares plunged Wednesday in reaction to a citizen petition calling for halting clinical studies of its lead drug candidate simufilam due to alleged data manipulation and misrepresentation.

Why Cassava Sciences Stock Investors Are Pulling Back

Axsome Therapeutics

AstraZeneca

Nasdaq

Novavax

Pieris Pharma

Roche Holding AG

Seagen

Sanofi

Over the last few years, three tiny biotechs emerged out of nowhere to give amazing returns to early investors. Which biotech might pull off a similar feat in 2022?

Which Biotech Stock Will Shock the Market in 2022?

Quanterix Corp. QTRX, -9.21% said that while it was previously engaged by Cassava Sciences Inc. SAVA, -12.38% to perform sample testing, the digitized biomarker analysis company said it, or its employees, "did not interpret the test results or prepare the data charts" presented by Cassava to the Alzheimer's Association International Conference (AAIC) in July, or otherwise. Earlier this week, in Cassava's response to a request the Food and Drug Administration halt clinical studies of Cassava's Alzheimer's treatment because of concerns over the accuracy and integrity of presented biomarker data, Cassava had said that data from Alzheimer's patients were generated by Quanterix.

Cassava's stock tumbles again, after Quanterix said it 'did not' prepare data charts presented by Cassava, that are under dispute

The petition filed against Cassava Sciences is so misleading and wrong-headed it seems an intentional act of FUD and not a serious request.

Specious Claims And Spurious Accusations Are All The Bears Can Muster Against Cassava Sciences

The stock price of Cassava Sciences, a clinical stage biotechnology company focused on treatment for Alzheimer's disease, has seen a large 31% decline in a single trading session on Aug 25. SAVA stock has had a volatile ride over the last year or so, and despite yesterday's fall, the stock is.

After A 30% Fall Cassava Stock Is Likely To See Lower Levels

NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Cassava Sciences, Inc. (“Cassava Sciences” or the “Company”) (NASDAQ: SAVA) on behalf of Cassava Sciences stockholders. Our investigation concerns whether Cassava Sciences has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On August 24, 2021, after the market

CASSAVA SCIENCES ALERT: Bragar Eagel & Squire, P.C. Is Investigating Cassava Sciences on Behalf of Cassava Sciences Stockholders and Encourages Investors to Contact the Firm

Boston, Massachusetts--(Newsfile Corp. - August 26, 2021) -  Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA), a drug development company.On August 25, 2021, Bloomberg reported that shares of Cassava were down 31% "after a lawyer sought to stop studies of the biotech company's experimental treatment for Alzheimer's disease." According to Bloomberg, "a citizen petition from a former Securities...

SAVA Alert: Berman Tabacco Investigates Cassava Sciences, Inc. for Potential Securities Claims in Connection with FDA Citizen Petition

LOS ANGELES--(BUSINESS WIRE)---- $SAVA #SAVA--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Cassava Sciences, Inc.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Cassava Sciences, Inc. and Encourages Investors with Losses to Contact the Firm

Cassava has received the go-ahead from the FDA to initiate two pivotal trials of its Alzheimer's therapy Simufilam. One week ago, however, a citizen's petition filed with the FDA insisted that data from earlier studies of Simufilam had been manipulated in various ways.

Cassava Sciences Likely To Survive Latest Attack On Alzheimer's Drug, But Caveat Emptor

Cassava (SAVA) plunges following charges against its scientific integrity in developing a drug for Alzheimer's disease. The company responds to the same.

News for Cassava Sciences Inc Stock (SAVA)